Cortical Dynamics of Inhibitory Control: A Concurrent tDCS-MEG Study (CDIC-tDCS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03484377 |
|
Recruitment Status :
Completed
First Posted : March 30, 2018
Last Update Posted : February 25, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Impulsive Behavior | Device: Anodal tDCS Device: Sham tDCS | Not Applicable |
Concurrent tDCS-MEG parallel arms single-blinded experimental design (right anodal v sham tDCS) will be employed in this study. The study will be conducted at the University of Nottingham, using a sample of student volunteers. This study aims to examine the influence of anodal tDCS on beta-band and alpha-band oscillatory activities, using an anti-saccade task administered before, during and after tDCS stimulation. It can potentially help understand the neurobiological mechanisms underpinning rapid response impulsivity and how these can be influenced by tDCS.
The research hypotheses are that (i) a generalised mechanism for top-down inhibitory control will play a vital role, whereby prefrontal beta-band activity initiates alpha-band activity for functional inhibition over the frontal eye fields and other areas in the neurocircuitry involved in RRI; (ii) anodal tDCS (as opposed to sham) delivered over the right DLPFC will enhance this mechanism; and (iii) there will be no significant correlations between measures of self-report impulsivity and performance on the anti-saccade task and measures of oscillatory activity.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 36 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Concurrent tDCS-MEG parallel arms single-blinded experimental design (right anodal v sham tDCS). |
| Masking: | Single (Participant) |
| Masking Description: | Participants will be randomly allocated, using a computer generated code, to receive either anodal tDCS or sham. For sham stimulation, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session |
| Primary Purpose: | Treatment |
| Official Title: | Measuring Cortical Dynamics of Inhibitory Control Before, During and After Transcranial Direct Current Stimulation (tDCS) |
| Actual Study Start Date : | September 15, 2018 |
| Actual Primary Completion Date : | February 14, 2019 |
| Actual Study Completion Date : | February 28, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Anodal tDCS
The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
|
Device: Anodal tDCS
The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. |
|
Sham Comparator: Sham tDCS
The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
|
Device: Sham tDCS
The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes. |
- Total number of correct anti-saccade (AS) trials [ Time Frame: Change from baseline after 20 minutes of tDCS ]A measure of rapid response impulsivity (inhibitory control)
- Total number of correct pro-saccade (PS) trials [ Time Frame: Change from baseline after 20 minutes of tDCS ]A behavioral measure of rapid response impulsivity (inhibitory control)
- Saccade latency for anti-saccade (AS) trials [ Time Frame: Change from baseline after 20 minutes of tDCS ]A behavioral measure of rapid response impulsivity (inhibitory control)
- Saccade latency for pro-saccade (PS) trials [ Time Frame: Change from baseline after 20 minutes of tDCS ]A behavioral measure of rapid response impulsivity (inhibitory control)
- Total Scores on the UPPS+P Impulsive Behaviour Scale [ Time Frame: Baseline ]A self-report measure of impulsivity
- Alpha and Beta band activity [ Time Frame: Change from baseline after 20 minutes of tDCS ]A Cortical measure of inhibitory control recorded using Magnetoencephalography (MEG). MEG is a brain imaging technique.
- Alpha and Beta band activity [ Time Frame: During 20 minutes of tDCS stimulation ]Evaluation of mechanism of action of tDCS using MEG data
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- University students and staff
- Aged 18-40
Exclusion Criteria:
- Individuals with epilepsy and other neurological conditions, history of significant head injury, substance misuse, major mental disorder and those receiving psychotropic medication.
- Contraindications to use of Magnetic Resonance (pacemakers, metal implants, aneurysm clips)
- Pregnancy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03484377
| United Kingdom | |
| University of Nottingham | |
| Nottingham, Notts, United Kingdom, NG7 2TU | |
| Principal Investigator: | Najat Khalifa, DM | University of Nottingham |
Documents provided by Najat Khalifa, Nottinghamshire Healthcare NHS Trust:
| Responsible Party: | Najat Khalifa, Associate Professor, Nottinghamshire Healthcare NHS Trust |
| ClinicalTrials.gov Identifier: | NCT03484377 |
| Other Study ID Numbers: |
CiC2017051 199-1801 ( Other Identifier: Research Ethics - University of Nottingham ) |
| First Posted: | March 30, 2018 Key Record Dates |
| Last Update Posted: | February 25, 2020 |
| Last Verified: | February 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
|
Impulsive Behavior |

